Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-THP-APN09 is a radiopharmaceutical candidate designed for positron emission tomography (PET) imaging of Aminopeptidase N (APN/CD13) expression. It consists of the radioisotope Gallium-68 (68Ga) chelated by a tris(hydroxypyridinone) (THP) ligand, which is conjugated to the APN09 peptide. APN09 is a cyclic peptide ligand that specifically binds to CD13, a zinc-dependent metalloproteinase overexpressed on the surface of various tumor cells and neovascular endothelial cells during angiogenesis. The use of the THP chelator allows for rapid, high-affinity radiolabeling at room temperature and near-neutral pH, facilitating simplified "shake-and-shoot" radiopharmacy applications. This tracer is primarily investigated for its potential in detecting CD13-positive tumors and monitoring tumor-associated angiogenesis in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-THP-APN09.